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INTRODUCTION
Postmenopausal osteoporosis is a common condition in which reduced levels of oestrogen alter the mineral composition of bone, leading to a loss of mineralized bone tissue and structural failure (fracture) [1] [2] [3] [4] . To delay the loss of bone minerals and thereby prevent bone fractures, treatment strategies have included oestrogen replacement or the administration of selective oestrogen receptor modulators, such as raloxifene, bisphosphonates, and calcitonin. However, these therapies increase the risk of hypercalcemia, hypercalciuria, hot flushes, and endometrial cancer [5] [6] [7] . Interestingly, isoflavones are chemically similar to oestradiol (E2) and bind to both alpha-and beta-oestrogen receptors, resulting in either the stimulation of globulin production or inhibition of aromatase activity [8] . There is evidence that isoflavones reduce the risk of endometrial cancer by interfering with oestrogen hormone production and signalling. As a subclass of plant-based polyphenols, isoflavones are present in legumes and are in particularly high concentrations in soy products [8] . Thus, the dietary intake of these compounds may influence the deposition of minerals in bone tissue in individuals with low levels of oestrogen.
In this study, we examined whether the intake of dietary soy isoflavones impacts bone mineral density (BMD) to prevent bone loss in animals with oestrogen deficiencies. For this, we analysed the mineral composition and transcription of osteoblast-related genes in vertebral and femur tissues from ovariectomized (OVX) rats, which have been shown to demonstrate progressive losses of bone matrices [9] .
EXPERIMENTAL Isolation and HPLC analysis of soy isoflavones
Soy isoflavones were isolated from defatted soy flour. Briefly, the flour was mixed with 100 mL of a methanol-water solution (4:1 ratio) in a 150-mL glass tube that was rotated for 3 h at 30 rpm at 35 ± 0.1C. The solution was then placed under vacuum in a rotary evaporator to concentrate the extracts, which were then filtered and stored at -80°C.
The extracts were analysed by high-performance liquid chromatography (HPLC) using an HPLC system (Waters 2459; Waters Corp., Milford, MA, USA) with a 5-µm (4.6 × 250 mm) Waters Sunfire C 18 column maintained at 25C. HPLC was conducted with 20-μL injections, a 0.9-ml/min flow rate (Waters 515 HPLC pump), a 210-nm detection wavelength, and a run time of 30 min. For the mobile phase, we used an isopropanol and acetonitrile mixture (1:24 [vol/vol] ). Solutions of glycitin, daidzin, genistin daidzein, genistein, and glycitein were used as standards.
Animals
Forty-eight female wistar rats (3 months old; 230-250 g) were assigned randomly to groups of OVX rats receiving daily soy isoflavones (20, 30, or 40 mg/kg of body weight), untreated OVX rats, or untreated intact rats. Rats were anaesthetized with pentobarbital for surgeries to remove both ovaries; in the intact rats, the ovaries were exposed but not removed. The animals receiving treatments were given oral (intragastric administration) doses of isoflavones once daily for 8 weeks. The procedures in this study were approved by the ethics committee of Dalian Medical University.
All experimental protocols were approved by the Ethics Committee of Dalian Medical University (approval no. 170616) according to the guidelines put forth by the National Institutes of Health Guide for the Care and Use of Laboratory Animals [10] .
Assessment of BMD and composition
After 8 weeks, animals were anesthetized with pentobarbital for the measurement of the BMD of the lumbar vertebrae (L2 to L4) and the left femurs by dual-energy X-ray absorptiometry (Lunar, USA) as described previously [11] . The animals were sacrificed by CO 2 asphyxiation, and the length and width of each femur (midshaft) were measured with digital callipers. The concentrations of Ca, P, Mn, Mg, and Zn in bone tissue were determined by atomic absorption spectrometry (Type 180-70; Hitachi Co., Tokyo, Japan).
Biochemical analyses
Blood samples were collected prior to asphyxiation, and the resulting serum obtained after centrifugation (20 min at 3,000 rpm) was stored at -2 o C. Alkaline phosphatase (ALP) activities in serum were assayed with standard commercial colorimetric kits (ZhongSheng BeiKong Bio-technology and Science, China) on an automatic biochemical analyser (Cobas Integra 400 Plus; Roche Diagnostics, Switzerland).
A double-antibody radioimmunoassay kit was used to determine osteocalcin (BGP) and E2 levels on a gammaray counter [12] .
Quantitative real-time PCR
Trizol reagent (Invitrogen) was used to extract total RNA from bone tissues for quantitative realtime PCR with SYBR green on a Light Cycler 480 II (Roche Diagnostics). The expressions of osteoblast-specific osterix (Sp7), -catenin (Ctnnb1), runt-related transcription factor 2 (Runx2), and -actin (Actb; reference gene) were determined by using the primers listed in Table 1 . Each reaction was performed in triplicate and was repeated three times. Relative cycle threshold (C T ) values were used to quantify gene expression according to the 2 -CT method. 
Western blot
Total proteins from 50-mg samples of bone and muscle tissue were extracted with RIPA lysis buffer. A BCA protein assay (Pulilai, China) was used to measure protein concentrations. Protein samples (80 μg) were separated by SDS-PAGE on 10 % gels and transferred to polyvinylidene difluoride membranes. The membranes were first incubated for 3 h in 5% non-fat-milk blocking solution at room temperature, followed by an overnight incubation at 4C with anti-Notch1 or anti-Gapdh antibodies (1:1,000). After incubating with appropriate secondary antibodies, the proteins were visualized via enhanced chemiluminescence. The densities of the bands for each protein were measured using ImageJ (National Institutes of Health, USA), and Notch1 expression was normalized to that of Gapdh.
Statistical analysis
Data are presented as mean ± SD and were analysed by one-way analysis of variance using SPSS software (version 12.0). P <0.05 was considered statistically significant.
RESULTS
The isoflavone composition of the extracts was 2.13479 ng/μL genistin, 13.86087 ng/μL glycitin, 4.15441 ng/μL daidzin, 32.23469 ng/μL genistein, and 34.26970 ng/μL daidzein, ( Figure  1 ).
Ovariectomy significantly reduced the mean BMD values after 8 weeks (p < 0.05) (Figure 3 ). However, daily soy isoflavone supplementation dose-dependently increased BMD values in OVX rats. The average initial and final body weights from all groups are presented in Figure 2 . Over the 8-week study, the body weights of all animals increased; however, the OVX rats were significantly heavier than those of the intact group (p < 0.05). Isoflavone supplementation attenuated the weight increase over the 8-week study in a dose-dependent manner. ) in OVX rats. 1, intact rats; 2, untreated OVX rats; 3-5, OVX rats treated with 20, 30, or 40 mg/kg isoflavones, respectively; *p < 0.05, **p < 0.01 Serum levels of BGP, ALP, and E2 measured after 8 weeks were significantly (p < 0.01) higher in intact rats than in OVX rats (Table 2) . Furthermore, the administration of soy isoflavones dose-dependently increased serum BGP, ALP, and E2 levels in OVX rats. Daily soy isoflavone supplementation also affected the concentrations of Ca, P, Mg, Mn, and Zn in bone tissues as shown in Table 3 . The levels of all elements were significantly higher in intact rats than in untreated OVX rats. However, the administration of soy isoflavones to OVX rats significantly and dose-dependently increased Ca, P, Mg, Mn, and Zn concentrations compared to those in the untreated OVX model group. The maximum lumbar load capacity was significantly reduced after 8 weeks in OVX rats ( Figure 4 ). However, animals receiving isoflavone supplementation demonstrated significantly higher (p < 0.05) load capacities than those of the untreated OVX rats, an effect that also appeared to be dose dependent.
We also measured gene expression levels in bone tissue samples. We found that relative to the levels in intact animals, the transcription of genes encoding β-catenin, runt-related transcription factor 2, and osterix (Ctnnb1, Runx2, and Sp7, respectively) were reduced in the femurs of OVX rats (Table 4) . However, the levels of all three transcripts were significantly higher (p < 0.05) in the OVX rats that were treated with soy isoflavones, with the largest difference observed with the high-dose soy isoflavone treatment. We also examined the protein expression of Notch1 in samples of femur and muscle tissue. There was a dramatic loss of Notch1 protein in the femurs and muscles of OVX rats ( Figure 5 A and B, respectively). However, daily treatment with soy isoflavones increased the expression of Notch1 protein significantly (p < 0.05) in OVX rats. The effect was most pronounced in animals treated with a high-dose of soy isoflavones.
DISCUSSION
The loss of bone and bone strength in individuals with osteoporosis contributes to fractures as a result of longer durations of resorption phases during bone remodelling [13] . During menopause, this enhancement of bone resorpt- tion is at the expense of osteoplastic replacement, resulting in reduced bone formation [14, 15] .
Thus, we examined whether isoflavones, which can mimic some of the actions of oestrogen, can influence this process and suppress bone loss. It was observed that supplementation with dietary soy isoflavones inhibited OVX-induced osteoporosis in rats. The effect was observed in BMD and serum levels of ALP and BGP, which are indicators of bone formation and turnover. Whereas ALP catalyses osteoid formation and bone mineralization, BGP is a non-collagenous protein that regulates bone mineralization and suppresses abnormal hydroxyapatite crystallization and cartilage mineralization, thereby balancing bone remodelling processes [16] [17] [18] . Accordingly, we observed that OVX animals treated with soy isoflavones had increased concentrations of Ca, P, Mg, Mn, and Zn in bone, which are indicators of the mineral content and degree of mineralization in bone tissue [19] . Moreover, soy isoflavones dosedependently restored the transcription of osteoblast-related genes (Ctnnb1, Runx2, and Sp7) in OVX rats. Thus, the high-dose administration of soy isoflavones inhibited the OVX-induced bone loss, which was demonstrated by an increase in the maximum load capacity of lumbar vertebrae.
Notch1 is one of the four Notch proteins, which are transmembrane receptors that regulate highly conserved cell-fate decisions during embryonic development and throughout adulthood, including in the placenta during pregnancy [20] . Notch1 also regulates the differentiation and decidualization of stromal cells in the endometrium [20] . The expression of Notch1 dropped dramatically in OVX rats but was restored by supplementation with dietary isoflavones.
CONCLUSION
The results demonstrate that soy isoflavones inhibit bone loss and alleviate osteoporosis in rats, in part, via upregulation of Notch signalling. This suggests that soy isoflavones can potentially be applied to mitigate the effects of postmenopausal bone loss.
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